HC Wainwright Weighs in on Delcath Systems Q1 Earnings

Key Points

• HC Wainwright maintained a Buy rating and a $32 price target for Delcath Systems, forecasting Q1 2027 EPS of $(0.05), followed by projected EPS of $0.12, $0.00, and $0.02 in the subsequent quarters.
• Delcath’s latest quarterly results exceeded expectations, with EPS of $0.07 versus the estimated $(0.09) loss and revenue of $29.13 million versus the $26.25 million consensus.
• Analyst sentiment is generally positive: five analysts rate the stock Buy, one Hold, and one Sell, resulting in a “Moderate Buy” consensus and an average price target of $23.17.

Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Delcath Systems in a report released on Friday, August 7th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for Delcath Systems' current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Delcath Systems' Q2 2027 earnings at $0.12 EPS, Q3 2027 earnings at $0.00 EPS and Q4 2027 earnings at $0.02 EPS.

Other research analysts also recently issued reports about the stock. Weiss Ratings raised shares of Delcath Systems from a "sell (d)" rating to a "sell (d+)" rating in a research report on Monday, May 11th. BTIG Research lifted their price target on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday. Wall Street Zen upgraded Delcath Systems from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Zacks Research raised Delcath Systems from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $23.17.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $15.11 on Monday. The company has a market capitalization of $524.32 million, a PE ratio of 1,512.51 and a beta of 0.52. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $16.38. The company has a 50-day simple moving average of $12.35 and a 200 day simple moving average of $10.88.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.16. The company had revenue of $29.13 million for the quarter, compared to the consensus estimate of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%.

Hedge Funds Weigh In On Delcath Systems

Several large investors have recently modified their holdings of DCTH. Deutsche Bank AG raised its holdings in Delcath Systems by 5.4% during the 4th quarter. Deutsche Bank AG now owns 24,162 shares of the company's stock valued at $244,000 after acquiring an additional 1,248 shares during the period. California State Teachers Retirement System purchased a new position in shares of Delcath Systems in the second quarter valued at $26,000. Intech Investment Management LLC raised its stake in shares of Delcath Systems by 13.1% during the 4th quarter. Intech Investment Management LLC now owns 17,595 shares of the company's stock valued at $178,000 after purchasing an additional 2,035 shares during the period. AWM Investment Company Inc. raised its stake in shares of Delcath Systems by 3.9% during the 4th quarter. AWM Investment Company Inc. now owns 60,000 shares of the company's stock valued at $606,000 after purchasing an additional 2,279 shares during the period. Finally, Royal Bank of Canada lifted its holdings in Delcath Systems by 14.8% during the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company's stock worth $170,000 after purchasing an additional 2,364 shares in the last quarter. Hedge funds and other institutional investors own 61.12% of the company's stock.

Key Stories Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Quarterly earnings beat expectations: Delcath reported second-quarter earnings of $0.07 per share, versus the consensus estimate for a $0.09 loss, while revenue of $29.13 million exceeded expectations of $26.25 million. Earnings matched the year-ago quarter and represent a significant improvement relative to analyst forecasts. MarketBeat earnings report Zacks earnings coverage
• Positive Sentiment: Revenue outlook is above consensus: The company issued fiscal 2026 revenue guidance of $104 million to $108 million, ahead of the approximately $103.3 million analyst consensus. The outlook reinforces expectations for continued commercial growth. Benzinga guidance coverage
• Positive Sentiment: Analyst price target increased: BTIG Research raised its DCTH price target from $17 to $21 and maintained a Buy rating, signaling greater confidence in the company’s growth prospects and implying substantial potential upside from recent trading levels. Benzinga analyst coverage
• Positive Sentiment: Momentum and investor attention increased: Coverage highlighted DCTH’s best trading session in nearly 15 months and a new 52-week high, while volume was more than twice its recent average. These technical signals likely amplified the reaction to the earnings beat. MSN 52-week-high coverage
• Neutral Sentiment: Investors are assessing the earnings-call outlook: Management’s second-quarter conference call focused on operating performance and the updated fiscal 2026 outlook. The guidance is encouraging, although the stock’s valuation remains demanding, with a very high reported price-to-earnings ratio. Seeking Alpha earnings call transcript

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company's core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source